F7Y Stock Overview
Engages in the research and development, production, and distribution of ophthalmic medical equipment and consumables, and the provision of technical services to end customers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Gaush Meditech Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.68 |
| 52 Week High | HK$2.36 |
| 52 Week Low | HK$0.57 |
| Beta | -0.24 |
| 1 Month Change | 17.39% |
| 3 Month Change | -39.19% |
| 1 Year Change | -70.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| F7Y | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.7% | 0.8% | 0.8% |
| 1Y | -70.4% | -9.3% | 15.0% |
Return vs Industry: F7Y underperformed the German Medical Equipment industry which returned -9% over the past year.
Return vs Market: F7Y underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| F7Y volatility | |
|---|---|
| F7Y Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: F7Y has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: F7Y's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 884 | Xinwei Liu | www.gaush.com |
Gaush Meditech Ltd. engages in the research and development, production, and distribution of ophthalmic medical equipment and consumables, and the provision of technical services to end customers. The company’s product portfolio comprising proprietary products, which it develops and manufactures, as well as distribution products of its brand partners, which it distributes, covering seven ophthalmology sub-specialties where ophthalmic medical devices are utilized for diagnosis, treatment, or surgeries, being vitreoretinal diseases, cataracts, refractive surgery, glaucoma, ocular surface diseases, optometry, and pediatric ophthalmology. Gaush Meditech Ltd.
Gaush Meditech Ltd Fundamentals Summary
| F7Y fundamental statistics | |
|---|---|
| Market cap | €100.78m |
| Earnings (TTM) | €11.39m |
| Revenue (TTM) | €176.15m |
Is F7Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| F7Y income statement (TTM) | |
|---|---|
| Revenue | CN¥1.43b |
| Cost of Revenue | CN¥774.43m |
| Gross Profit | CN¥653.96m |
| Other Expenses | CN¥561.57m |
| Earnings | CN¥92.39m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 45.78% |
| Net Profit Margin | 6.47% |
| Debt/Equity Ratio | 32.0% |
How did F7Y perform over the long term?
See historical performance and comparisonDividends
Does F7Y pay a reliable dividends?
See F7Y dividend history and benchmarks| Gaush Meditech dividend dates | |
|---|---|
| Ex Dividend Date | Jun 23 2025 |
| Dividend Pay Date | Jul 25 2025 |
| Days until Ex dividend | 34 days |
| Days until Dividend pay date | 66 days |
Does F7Y pay a reliable dividends?
See F7Y dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 06:55 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gaush Meditech Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Youjue Hu | Morgan Stanley |